P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTI...

por Lowther, D.E., Houseman, E.A., Han, G., Kleanthous, E., Knoblock, D., Zhou, X., Banerjee, S., Patel, S., Figueroa, D.
Publicado 2023